placeholder image
S. R. Heller All authors
About
Publications While At 开云体育
selected publications
Journal Article
  • Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. 
    Diabetes, Obesity & Metabolism. 2021
  • Alogliptin in patients with type 2 diabetes receiving metformin and sulfonylurea therapies in the EXAMINE Trial. 
    American Journal of Medicine. 2018
  • Average clinician-measured blood pressures and cardiovascular outcomes in patients with type 2 diabetes mellitus and ischemic heart disease in the EXAMINE Trial. 
    Journal of the American Heart Association. 2018
  • High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. 
    Diabetes, Obesity & Metabolism. 2018
  • Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. 
    Clinical Cardiology. 2018
  • Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). 
    Diabetes care. 2017
  • Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: the EXAMINE trial. 
    Diabetes, Obesity & Metabolism. 2017
  • Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE Trial. 
    Diabetes care. 2016
  • Alogliptin after acute coronary syndrome in patients with type 2 diabetes. 
    New England Journal of Medicine. 2013
  • EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. 
    American Heart Journal. 2011
    • Review
  • Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time-in-Range [review]. 
    Diabetes care. 2019
  • International consensus on use of continuous glucose monitoring [review]. 
    Diabetes care. 2017
    • Abstract
  • Alogliptin in triple therapy with metformin and sulfonylureas provides significant reductions in HbA1c and is well tolerated: an analysis from the EXAMINE Trial [abstract]. 
    Diabetes. 2016
  • Double-blind mealtime faster-acting insulin aspart vs. insulin aspart in basal-bolus improves glycemic control in T1D: the Onset 1 Trial [abstract #293-OR]. 
    Diabetes. 2016
  • Hypoglycemia is associated with increased risk of cardiovascular events: results from the EXAMINE Trial [abstract]. 
    Diabetes. 2016
  • Mortality findings from the EXAMINE Trial [abstract]. 
    Diabetes. 2016
  • Major cardiovascular outcomes in the EXAMINE trial according to ACE inhibitor use [abstract]. 
    Diabetes. 2015
    • Contact
    full name
  • S. R. Heller
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration